Our website uses cookies to enhance and personalize your experience and to display advertisements (if any). Our website may also include third party cookies such as Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click the button to view our Privacy Policy.

AI uncovers 1,108 candidate proteins on human cell surface absent from five major databases

Deliverome uses AI to map the human cell surface and flags 1,108 candidate drug targets
Contents
  1. Databases that disagree
  2. How the tool works
  3. A case in point: the KLK2 protein
  4. An open resource
  5. References

More than 65% of approved medicines work by binding to proteins on the surface of human cells, yet the major biological databases disagree on which proteins are actually there. The Deliverome Project, an open research initiative, used artificial intelligence to review the published evidence and build a map of the human surfaceome, the full set of cell surface proteins.

The map pinpoints 1,108 candidate proteins that are absent across all five primary reference databases yet backed by published research. Released in October 2026 as a preprint on bioRxiv, these insights lack formal peer review so far, meaning the proteins remain candidates instead of verified targets.

Databases that disagree

The team compared five databases: UniProt, GO CC, the Human Protein Atlas, the Cell Surface Protein Atlas and SURFY. Together they list 5,546 surface proteins, but all five agree on only 188, according to the Hertz Foundation.

How the tool works

Co-founders Becca Carlson and Bobby Hollingsworth built an AI agent using the Claude Sonnet 4.6 model. The agent reviews the scientific literature to determine whether a protein sits on the cell surface.

On SurfaceBench, a hand-labeled collection consisting of 147 proteins, the agent achieved a 95.7% classification accuracy, whereas UniProt, which stood out as the top-performing database, reached roughly 90%.

A case in point: the KLK2 protein

All five databases classify the protein KLK2 as absent from the cell surface. However, research has found a membrane-anchored form enriched in prostate cancer, and an experimental therapy targeting it is in Phase 3 trials. Deliverome classifies KLK2 as able to appear on the surface under certain conditions.

An open resource

The map is free to explore in Open View, an interactive tool that showcases each protein next to its corresponding research. Additionally, the initiative provides a public API alongside open-source code.

“My hope is that this will help people develop drugs that are more diverse and serve more patients and more indications,” said Carlson, a 2017 Hertz Fellow and the project’s co-CEO.

Deliverome launched on May 27, 2026, with $5 million in seed funding from the Astera Institute. It is set up as a Focused Research Organization, a model designed to deliver public research tools within about five years. Researchers from Coral Biosciences also co-authored the preprint.

References

By Mia Murphy

You may also like